Stocksigma LogoStocksigma Logo

Sai Parenterals Reports Robust Q2FY27 Results and Advances Major Expansion Capex

Sai Parenterals delivered Q2FY27 consolidated revenue of Rs. 196.1 cr (up 9.0% QoQ, 257.4% YoY) with EBITDA surging 67.4% QoQ to Rs

Sai Parenterals Reports Robust Q2FY27 Results and Advances Major Expansion Capex

Sai Parenterals Ltd 路 Investor Presentation 路 02 Nov 2026, 1:43 am

Sai Parenterals Reports Robust Q2FY27 Results and Advances Major Expansion Capex Sai Parenterals delivered Q2FY27 consolidated revenue of Rs. 196.1 cr (up 9.0% QoQ, 257.4% YoY) with EBITDA surging 67.4% QoQ to Rs. 41.4 cr and PAT reaching Rs. 10.5 cr. H1FY27 revenue hit Rs. 376.0 cr against its full-year FY27 target of Rs. 750 cr. The company completed acquisitions of 60% stakes in Saicriti Pharma (Rs. 83.83 cr) and Sai Prathyak Laboratories (Rs. 15.0 cr) on 5th Oct'26, utilizing reallocated IPO proceeds. Ongoing Rs. 571 cr group capex remains on track, targeting EU-GMP/USFDA-ready injectable scale by Jul'27.

Original exchange filing (PDF)

More announcements from Sai Parenterals Ltd

All Sai Parenterals Ltd announcements